Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma

Nivolumab plus ipilimumab (nivo + ipi) is a standard treatment of advanced melanoma. Two randomized trials describe high objective response rates by Response Evaluation Criteria in Solid Tumors. The trials assessed toxic effects using the Common Terminology Criteria for Adverse Events (CTCAE), which...

Full description

Saved in:

Bibliographic Details
Published in:	JAMA oncology Vol. 4; no. 1; p. 98
Main Authors:	Shoushtari, Alexander N, Friedman, Claire F, Navid-Azarbaijani, Pedram, Postow, Michael A, Callahan, Margaret K, Momtaz, Parisa, Panageas, Katherine S, Wolchok, Jedd D, Chapman, Paul B
Format:	Journal Article
Language:	English
Published:	United States 01.01.2018
Subjects:	Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use Compassionate Use Trials Disease Progression Disease-Free Survival Drug-Related Side Effects and Adverse Reactions - epidemiology Female Humans Incidence Ipilimumab - administration & dosage Ipilimumab - adverse effects Male Melanoma - drug therapy Melanoma - epidemiology Melanoma - pathology Middle Aged Nivolumab - administration & dosage Nivolumab - adverse effects Prospective Studies Skin Neoplasms - drug therapy Skin Neoplasms - epidemiology Skin Neoplasms - pathology Time Factors Treatment Failure Young Adult
ISSN:	2374-2445, 2374-2445
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!